Cargando…

Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

BACKGROUND: Immunotherapy in the treatment of metastatic melanoma and renal cell carcinoma can produce durable therapeutic responses, which may improve survival. We aimed to identify clinical characteristics and biomarkers associated with response to high-dose interleukin-2 therapy (IL-2) in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saraceni, Christine, Agostino, Nicole, Weiss, Michael J, Harris, Katherine, Nair, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366439/ https://www.ncbi.nlm.nih.gov/pubmed/25815245 http://dx.doi.org/10.1186/s40064-015-0890-1

Ejemplares similares

A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma
por: Agostino, Nicole Marie, et al.
Publicado: (2015)

The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
por: Pachella, Laura A., et al.
Publicado: (2015)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
por: Ridolfi, Laura, et al.
Publicado: (2014)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996)

Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
por: Bulgarelli, Jenny, et al.
Publicado: (2021)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
por: Achkar, Tala, et al.
Publicado: (2017)

Single-agent interleukin-2 in the treatment of metastatic melanoma
por: Petrella, T., et al.
Publicado: (2007)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Dystonia in a Patient with Melanoma Metastatic to the Brain Treated with High-Dose Interleukin-2, Radiation Therapy, and Levetiracetam
por: Sreenivasan, Varun, et al.
Publicado: (2013)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
por: Clark, Joseph I., et al.
Publicado: (2018)

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients
por: Mehta, Kathan, et al.
Publicado: (2016)

Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
Publicado: (2020)

Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
por: Nikanjam, Mina, et al.
Publicado: (2022)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Plasmablastic lymphoma of the maxillary sinus in an HIV-negative patient: a case report and literature review
por: Saraceni, Christine, et al.
Publicado: (2013)

Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
por: Wang, Michael Z., et al.
Publicado: (2013)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

Metastatic Melanoma With Leptomeningeal Disease
por: Marinova, Amanda M., et al.
Publicado: (2021)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells
por: Minichsdorfer, Christoph, et al.
Publicado: (2015)

Auto-Rejection of Renal Donor-Origin Metastatic Melanoma
por: Kriegshauser, J. Scott, et al.
Publicado: (2015)

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
por: Mehta, Kathan, et al.
Publicado: (2015)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

Metastatic Melanoma with an Unknown Primary
por: Babu, Anuradha Kakkanatt, et al.
Publicado: (2022)

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
Publicado: (1996)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Hasanov, Merve, et al.
Publicado: (2021)

Interleukins in the treatment of melanoma
por: Xu, Xinyuan, et al.
Publicado: (2022)

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
por: Négrier, S., et al.
Publicado: (1992)

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
por: Payne, Roxanne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ovasehk601hq6n5jrrto4vnj01